Loading interactive chart...
1DInterval:
Date Range
1 min
Advertisement
MiMedx Group, Inc. (MDXG)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
Mountain
Settings
- GlobeNewswire
MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webc
- Zacks Small Cap Research
MDXG: Legal Avenues
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Since the report of 2023 full year results on February 28th, MiMedx Group, Inc. (NASDAQ:MDXG) has received an update on its request for designation for Axiofill from the FDA. It has also signed a commercialization agreement with TELA Bio to distribute xenograft products, introduced an e-commerce and account management
- GlobeNewswire
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administratio
Advertisement
Advertisement
Advertisement